(NASDAQ: AUTL) Autolus Therapeutics's forecast annual revenue growth rate of 203.7% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 64.61%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.18%.
Autolus Therapeutics's revenue in 2025 is $10,120,000.On average, 4 Wall Street analysts forecast AUTL's revenue for 2025 to be $11,557,445,869, with the lowest AUTL revenue forecast at $7,239,238,338, and the highest AUTL revenue forecast at $16,404,185,396. On average, 4 Wall Street analysts forecast AUTL's revenue for 2026 to be $41,330,084,299, with the lowest AUTL revenue forecast at $28,192,098,893, and the highest AUTL revenue forecast at $67,626,014,779.
In 2027, AUTL is forecast to generate $76,307,405,626 in revenue, with the lowest revenue forecast at $42,760,793,265 and the highest revenue forecast at $126,826,388,584.